Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Dow
Teva
McKinsey
Queensland Health
Boehringer Ingelheim
Johnson and Johnson
Citi

Generated: September 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,561,181

« Back to Dashboard

Title:Crystal forms
Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.
Inventor(s): Chen; Shuang (Gurnee, IL), Gates; Bradley D. (Mt. Prospect, IL), Sheikh; Ahmad Y. (Deerfield, IL)
Assignee: AbbVie Inc. (North Chicago, IL)
Filing Date:Apr 11, 2016
Application Number:15/095,474
Claims:1. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a solvent, thereby forming a solution, ##STR00002## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) as described in (a) any one of Tables 1a, 2a, 3a, and 4a or (b) any one of FIGS. 1-4.

2. The process of claim 1, wherein the solution further comprises an excipient.

3. The process of claim 1, wherein the solution further comprises a surfactant.

4. The process of claim 1, further comprising spray drying the solution, thereby forming a solid dispersion.

5. The process of claim 2, further comprising spray drying the solution, thereby forming a solid dispersion.

6. The process of claim 3, further comprising spray drying the solution, thereby forming a solid dispersion.

7. The process of claim 1, further comprising freeze drying the solution, thereby forming a solid dispersion.

8. The process of claim 2, further comprising freeze drying the solution, thereby forming a solid dispersion.

9. The process of claim 3, further comprising freeze drying the solution, thereby forming a solid dispersion.

10. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a solvent, thereby forming a solution, ##STR00003## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 11.1, 12.2, 14.5, 15, 15.9, 17.4, 17.8, and 22.2.

11. The method of claim 10, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 19.6, 19.9, 21.1, 22.2, 22.7, and 23.9.

12. The method of claim 11, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 6.7, 8.4, 8.9, 9.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 18.1, 18.9, 19, 19.6, 19.9, 21.1, 21.8, 22.2, 22.7, 22.8, 23.2, 23.9, 24.6, and 25.1.

13. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a molten hydrophilic polymer, thereby forming a melt, ##STR00004## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) as described in (a) any one of Tables 1a, 2a, 3a, and 4a or (b) any one of FIGS. 1-4.

14. The process of claim 13, wherein the melt further comprises an excipient.

15. The process of claim 13, wherein the melt further comprises a surfactant.

16. The process of claim 14, further comprising solidifying the melt, thereby forming a solid dispersion.

17. The process of claim 14, further comprising solidifying the melt, thereby forming a solid dispersion.

18. The process of claim 15, further comprising solidifying the melt, thereby forming a solid dispersion.

19. The process of claim 13, wherein the hydrophilic polymer is copovidone.

20. A process for making a pharmaceutical composition comprising Compound I, comprising dissolving a crystalline form of Compound I in a molten hydrophilic polymer, thereby forming a melt, ##STR00005## wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 11.1, 12.2, 14.5, 15, 15.9, 17.4, 17.8, and 22.2.

21. The method of claim 20, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 8.4, 8.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 19.6, 19.9, 21.1, 22.2, 22.7, and 23.9.

22. The method of claim 21, wherein said crystalline form has characteristic peaks in its PXRD pattern at values of two theta (.degree.2.theta.) of 6.7, 8.4, 8.9, 9.9, 10.2, 11.1, 12.2, 12.5, 13.2, 13.7, 14.5, 15, 15.5, 15.9, 17.4, 17.8, 18.1, 18.9, 19, 19.6, 19.9, 21.1, 21.8, 22.2, 22.7, 22.8, 23.2, 23.9, 24.6, and 25.1.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Harvard Business School
Cerilliant
Moodys
Baxter
Deloitte
Julphar
Medtronic
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.